Lyra Therapeutics Withdraws Appeal of Nasdaq Delisting Determination

Lyra Therapeutics Inc has withdrawn its appeal of Nasdaq's delisting determination. The biotechnology company is focused on developing therapies for chronic rhinosinusitis, a prevalent inflammatory disease of the paranasal sinuses. Lyra has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS. These bioresorbable nasal implants deliver continuous mometasone furoate drug therapy to the sinonasal passages for six months. LYR-210 is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220 is being evaluated in the BEACON Phase II clinical trial.